NO20030064L - Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X - Google Patents

Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X

Info

Publication number
NO20030064L
NO20030064L NO20030064A NO20030064A NO20030064L NO 20030064 L NO20030064 L NO 20030064L NO 20030064 A NO20030064 A NO 20030064A NO 20030064 A NO20030064 A NO 20030064A NO 20030064 L NO20030064 L NO 20030064L
Authority
NO
Norway
Prior art keywords
syndrome
prevention
development
type
diabetes mellitus
Prior art date
Application number
NO20030064A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030064D0 (no
Inventor
Carlos R Plata-Salaman
Jeffrey Crooke
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NO20030064D0 publication Critical patent/NO20030064D0/no
Publication of NO20030064L publication Critical patent/NO20030064L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20030064A 2000-07-07 2003-01-06 Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X NO20030064L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21714100P 2000-07-07 2000-07-07
US27002201P 2001-02-20 2001-02-20
PCT/US2001/021404 WO2002003984A2 (en) 2000-07-07 2001-07-06 Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x

Publications (2)

Publication Number Publication Date
NO20030064D0 NO20030064D0 (no) 2003-01-06
NO20030064L true NO20030064L (no) 2003-03-06

Family

ID=26911655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030064A NO20030064L (no) 2000-07-07 2003-01-06 Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X

Country Status (22)

Country Link
US (2) US6852701B2 (enExample)
EP (1) EP1309324B1 (enExample)
JP (1) JP4920163B2 (enExample)
CN (1) CN101404993A (enExample)
AR (1) AR032465A1 (enExample)
AT (1) ATE320805T1 (enExample)
AU (1) AU2001280486A1 (enExample)
BR (1) BR0112519A (enExample)
CA (1) CA2415093A1 (enExample)
DE (1) DE60118206T2 (enExample)
DK (1) DK1309324T3 (enExample)
ES (1) ES2260261T3 (enExample)
HU (1) HUP0302307A3 (enExample)
IL (1) IL153713A0 (enExample)
MX (1) MXPA03000136A (enExample)
MY (1) MY126897A (enExample)
NO (1) NO20030064L (enExample)
NZ (1) NZ523531A (enExample)
PL (1) PL365680A1 (enExample)
PT (1) PT1309324E (enExample)
RU (1) RU2268720C2 (enExample)
WO (1) WO2002003984A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7208477B2 (en) 2002-12-02 2007-04-24 University Of Florida Research Foundation, Inc. Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PE20060500A1 (es) * 2004-08-24 2006-07-13 Janssen Pharmaceutica Nv Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
BRPI0610864A2 (pt) * 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN102114002B (zh) * 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
AU2008209320B2 (en) * 2007-01-25 2013-05-30 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
JP6055076B2 (ja) 2012-03-23 2016-12-27 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ シネフリン及びトピラマートを含む組み合わせ製品
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
SK284305B6 (sk) * 1996-06-28 2005-01-03 Ortho-Mcneil Pharmaceutical, Inc. Liečivo na liečbu obezity
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
ES2238999T3 (es) 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
US6191163B1 (en) * 1999-04-08 2001-02-20 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
JP2003530300A (ja) 1999-04-08 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 体重低下を維持することに有用な抗痙攣薬誘導体
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
WO2000076493A1 (en) * 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity

Also Published As

Publication number Publication date
PT1309324E (pt) 2006-06-30
DE60118206D1 (de) 2006-05-11
WO2002003984A2 (en) 2002-01-17
US20040209824A1 (en) 2004-10-21
DK1309324T3 (da) 2006-06-12
HUP0302307A3 (en) 2007-05-29
JP4920163B2 (ja) 2012-04-18
HUP0302307A2 (hu) 2003-10-28
EP1309324B1 (en) 2006-03-22
US7109174B2 (en) 2006-09-19
MY126897A (en) 2006-10-31
PL365680A1 (en) 2005-01-10
WO2002003984A3 (en) 2003-03-06
EP1309324A2 (en) 2003-05-14
IL153713A0 (en) 2003-07-06
US6852701B2 (en) 2005-02-08
MXPA03000136A (es) 2004-09-13
CN101404993A (zh) 2009-04-08
AR032465A1 (es) 2003-11-12
AU2001280486A1 (en) 2002-01-21
NZ523531A (en) 2005-07-29
JP2004510700A (ja) 2004-04-08
ATE320805T1 (de) 2006-04-15
ES2260261T3 (es) 2006-11-01
RU2268720C2 (ru) 2006-01-27
CA2415093A1 (en) 2002-01-17
NO20030064D0 (no) 2003-01-06
DE60118206T2 (de) 2006-12-14
US20020037861A1 (en) 2002-03-28
BR0112519A (pt) 2004-03-30

Similar Documents

Publication Publication Date Title
NO20030064D0 (no) Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X
WO2002064210A3 (en) Combination therapy comprising anti-diabetic and anticonvulsant agents
NL1016224A1 (nl) Foto-basevormend middel en foto-zuurvormend middel bevattende foto- etssamenstelling.
NO20023566D0 (no) Propionsyrederivater og deres anvendelse ved behandling av sukkkersyke og fedme
NO20041160L (no) Bio-avlesningsplattform for pavisning og kvantitering av biologiske molekyler
DK1210380T3 (da) Sammenfoldelige oftalmiske og otorhinolaryngologiske anordningsmaterialer
ATE458718T1 (de) Alpha-cyanoacrylate
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20011196D0 (no) Raffinærskivesensor og sensorraffinærskive
AU2003258997A1 (en) Dram supporting different burst-length accesses without changing the burst length setting in the mode register
DE60137810D1 (de) Flüssigkristallverbindungen, Flüssigkristallmedium und Flüssigkristallanzeige
NO20030034D0 (no) En kombinasjon av FBPase inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes
NO20030800D0 (no) Aminoalkylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte forderes fremstilling og preparater inneholdende de samme
NO20030882L (no) Glasskeramikkmasse og anvendelse derav
AU2001250481A1 (en) Transparent substrate comprising metal elements and use thereof
DK1173436T3 (da) Thiazolidindionderivat og anvendelse deraf som antidiabetikum
ATE317386T1 (de) Dihydroindol- und tetrahydrochinolinderivate
AU2001241709A1 (en) Molecules for disease detection and treatment
NO20026065D0 (no) Prosesser for måling av dinofysistoksin og av yessotoksin
AU2002239543A1 (en) Molecules for disease detection and treatment
AU4471501A (en) Detection film and optical sensor using detection film
NO20015519D0 (no) Farmasöytisk sammensetning omfattende apokodein og/eller dets derivater
NO20004342D0 (no) Kvartstrykksensor
AU2001282245A1 (en) Two-wave temperature-stabilised optical interferometer and wavelength interleaving device comprising same
NO20014688D0 (no) Trykk- og pregeteknikk i flytende glass

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application